Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 12, 2020 at 02:55 pm
Share
Chunghwa Chemical Synthesis & Biotech Co., Ltd. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 284.623 million compared to TWD 217.018 million a year ago. Operating income was TWD 31.100 million compared to TWD 23.754 million a year ago. Net income was TWD 34.414 million compared to TWD 25.497 million a year ago. Basic earnings per share was TWD 0.44 compared to TWD 0.33 a year ago. For the nine months, sales was TWD 983.975 million compared to TWD 880.509 million a year ago. Operating income was TWD 146.038 million compared to TWD 76.730 million a year ago. Net income was TWD 433.317 million compared to TWD 80.041 million a year ago. Basic earnings per share was TWD 5.59 compared to TWD 1.03 a year ago. Diluted earnings per share was TWD 5.56 compared to TWD 1.03 a year ago.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. 
